Wells Fargo analyst Larry Biegelsen downgraded Edwards Lifesciences to Equal Weight from Overweight with a price target of $78, down from $97.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Bernstein medical tech/devices analysts hold analyst/industry conference call
- Edwards Lifesciences downgraded to Market Perform from Outperform at Raymond James
- Edwards Lifesciences downgraded to Market Perform at Raymond James
- Early notable gainers among liquid option names on February 1st
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord